Bernstein ups ArgenX on growth prospects driven by Vyvgart

argenx SE

17/03/2025 07:30

** Bernstein raises ArgenX to "outperform" from "underperform", citing a "phase change" driven by the Belgian biotech company's Vyvgart drug

** "We're increasing our 2030 group sales forecast by over 100% to $11 billion, which implies that key growth driver Vyvgart will become the 4th largest autoimmune drug ever," says Bernstein

** ArgenX has industry leading growth prospects, the broker adds

** Bernstein says risks are positively skewed and estimates a bull case share price upside of 138% if Vyvgart and empasiprubart are successfully commercialized in every segment where phase 3 trials are being conducted

** "'The market' isn't discounting all of Argenx's phase 3 trials and/or is overstating the potential competitive headwinds" - Bernstein

** From 19 analysts that cover ArgenX, 18 rate it "strong buy" or "buy" and ​one "hold"

 (Reporting by Dimitri Rhodes)

 ((Dimitri.rhodes@thomsonreuters.com))